Servier says its next IDH inhibitor has passed PhIII, but no regulatory timeline yet
Servier’s IDH inhibitor vorasidenib has passed its Phase III trial in low-grade glioma, the company announced Tuesday morning. However, it left …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
